Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Completed · Phase 1

Conditions studied: Psychotic Disorders, Schizophrenia

In brief

The purpose of this study is to explore the pharmacokinetics, safety and tolerability of a 4-week long-acting injectable (LAI) formulation of risperidone after single intramuscular (i.m.) injection of 75 mg risperidone LAI in the gluteal muscle.

Key facts

Study ID
NCT00821600
Run by
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
People needed
24
Starts
2008-12-01
Expected to finish
2009-06-01
Last updated by the study team
2014-05-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.